Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Detection and pathogenicity of human metapneumovirus respiratory infection in pediatric Italian patients during a winter–spring season

Antonella Sarasini, Elena Percivalle, Francesca Rovida, Giulia Campanini, Emilia Gennini, Maria Torsellini, Stefania Paolucci, Fausto Baldanti, Antonietta Marchi, M. Grazia Revello, Giuseppe Gerna

Servizio di Virologia IRCCS Policlinico San Matteo and University of Pavia, Via Taramelli 5, 27100 Pavia, Italy
Dipartimento di Pediatria, IRCCS Policlinico San Matteo and University of Pavia, Via Taramelli 5, 27100 Pavia, Italy

Received 2 October 2004; received in revised form 1 March 2005; accepted 7 May 2005

Abstract

Background: Some diagnostic, epidemiological and clinical features of the recently discovered human metapneumovirus remain to be investigated.

Objectives: To study the best approach for the diagnosis of human metapneumovirus infections by both conventional and molecular methods, along with the human metapneumovirus circulation rate in northern Italy and the severity of human metapneumovirus respiratory infections in a pediatric patient population.

Study design: Nasopharyngeal aspirates (NPA) were taken from 306 pediatric patients during the winter–spring season 2003–2004, and examined for conventional respiratory viruses by direct fluorescent staining and cell culture, while human coronavirus and human metapneumovirus were sought by RT-PCR.

Results: RT-PCR detected human metapneumovirus in 40/306 (13.1%) children positive for respiratory viruses, with an incidence intermediate between that of respiratory syncytial virus (58 patients, 18.9%) and that of influenzavirus infections (29 patients, 9.5%). Phylogenetic analysis showed cocirculation of both human metapneumovirus types (A and B) as well as their relevant subtypes (A1–A2 and B1–B2). Clinically, human metapneumovirus was found to be second to human respiratory syncytial virus alone, as a cause of respiratory tract infections, while duration of virus excretion appeared to correlate with severity of infection, and virus load in NPA with the stage of respiratory infection.

Conclusion: (i) Human metapneumovirus is a major viral pathogen in the Italian pediatric patient population; (ii) the severity of lower respiratory tract infections approaches that of human respiratory syncytial virus; (iii) there are preliminary indications that the duration of virus excretion may reach 2–3 weeks and that the level of viral load in NPA correlates with the clinical stage of human metapneumovirus infection.

© 2005 Elsevier B.V. All rights reserved.

Keywords: Human metapneumovirus; Human metapneumovirus isolation; RT-PCR; Phylogenesis

1. Introduction

Following the original report in 2001 (Van den Hoogen et al., 2001), human metapneumovirus has been repeatedly reported as a respiratory pathogen in early infancy as well as in the elderly and the immunocompromised host (Boivin et al., 2002; Bastien et al., 2003; Chan et al., 2003; Falsey et al., 2003; Maggi et al., 2003; Van den Hoogen et al., 2003; Williams et al., 2004). It is known that human metapneumovirus is a member (Van den Hoogen et al., 2002) of the same family (Paramyxoviridae) and subfamily (Pneumovirinae) of human respiratory syncytial virus, but belongs to a different genus (Metapneumovirus instead of Pneumovirus). The major reason why human metapneumovirus has not been
recovered previously from respiratory specimens is due to its difficulty to grow in cell cultures conventionally adopted for isolation of respiratory viruses. The recent identification of human metapneumovirus, first in The Netherlands and then in other countries, has been made possible by the use of molecular assays and, in particular, of the reverse transcription-polymerase chain reaction (RT-PCR).

Since the initial publication (Van den Hoogen et al., 2001), two major clusters (A and B) of human metapneumovirus have been detected by RT-PCR and reported to co-circulate. Although development of monoclonal antibodies (MAbs) for diagnostic use is being performed (Landry et al., 2005; Perrivalle et al., 2005), MAbs for direct antigen detection in nasopharyngeal aspirate (NPA) samples are not commercially available, and, thus, molecular assays represent the major approach currently available for human metapneumovirus identification. Although human metapneumovirus is considered a major cause of both upper and lower respiratory tract infections (RTIs), several aspects of human metapneumovirus infections remain to be defined. In particular, the severity of human metapneumovirus infections has not been entirely defined and no correlation between viral load in NPA and severity of clinical disease has yet been established (Boivin et al., 2002; Nissen et al., 2002; Bastien et al., 2003; Greensill et al., 2003; Maggi et al., 2003; Viazov et al., 2003; Esper et al., 2004; Hamelin et al., 2004; Williams et al., 2004; Van den Hoogen et al., 2004b). In addition, the duration of virus excretion during acute infection remains to be defined. Furthermore, as with other paramyxoviruses (Glezen et al., 1986) such as human respiratory syncytial virus, human metapneumovirus reinfections have been reported both in the immunocompetent (Van den Hoogen et al., 2003; Esper et al., 2004) and the immunocompromised host (Pelletier et al., 2002), yet this finding awaits confirmation.

In the present report, the following major issues will be addressed by taking advantage of the high circulation of human metapneumovirus in the winter–spring season 2003–2004: (i) circulation rate of human metapneumovirus among other respiratory viruses in northern Italy; (ii) severity of human metapneumovirus lower respiratory tract infections compared to human respiratory syncytial virus; (iii) duration of human metapneumovirus excretion and relationship between viral load in NPA and the stage of human metapneumovirus infection.

2. Materials and methods

2.1. Patients and nasopharyngeal aspirate collection

From 1 December 2003, through 31 May 2004, NPA samples were collected prospectively at the Department of Pediatrics, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy, from all infants and young children with acute respiratory infection admitted to the Emergency Section of the Department. Some patients were dismissed the same day, following completion of clinical, laboratory and radiological tests, whereas others were admitted to the Respiratory Disease Ward because of a more severe clinical presentation. Each NPA sample was divided into four aliquots: the first was used for molecular assays; the second was used for direct fluorescent antibody staining of NPA respiratory cells; the third was inoculated onto cell cultures for virus isolation (see below); the fourth was frozen in multiple aliquots as a back-up sample. Specimens were examined for influenza viruses A and B, para-influenza viruses types 1–4, human respiratory syncytial virus types A and B, and human adenoviruses by direct fluorescent antibody staining, and by short- and long-term virus isolation in cell cultures. In addition, human coronavirus strains, groups I (229E-like) and II (OC43-like), and human metapneumoviruses, types A and B, were sought by RT-PCR. Classification and typing of human respiratory syncytial virus strains was achieved by RT-PCR, grouping of human coronavirus strains by sequencing, and typing of human metapneumovirus strains by sequencing and phylogenetic analysis (see below). The study was approved by the IRCCS Policlinico San Matteo Ethics Committee. In this study, the simultaneous detection of two respiratory viruses in the same NPA was referred to as coinfection, while the subsequent identification of two different respiratory viruses in two NPAs taken within 30 days from each other was considered as a sequential infection.

2.2. Improved RT-PCR protocol

All RT-PCR assays for the identification of respiratory viruses were optimized to detect at least 10 input plasmid copies. To this purpose, primers were either selected from published protocols or originally designed from GenBank published virus sequences. Amplification products were then cloned in PCR2.1 plasmid vector (TA Cloning Kit, Invitrogen, Carlsbad, CA) to prepare quantitative standards. In addition, while reported thermal profiles or reaction mixtures had to be modified for some viruses, PCR protocols were redesigned and experimentally verified for other viruses. Respiratory viruses amplified by using PCR protocols derived from published papers were the following: influenza viruses A (H1N1) and B (Stockton et al., 1998), human parainfluenza virus-3 (Echevarria et al., 1998), human respiratory syncytial virus types A and B (Coiras et al., 2003), human adenovirus (Allard et al., 1991), human metapneumovirus type A (L gene, nt 4121–nt 4290), according to Van den Hoogen et al. (2003), and human coronaviruses (groups I and II) according to Poutanen et al. (2003). The newly designed primer pairs for influenza virus A (H1N2), human parainfluenza virus-1, human parainfluenza virus-2, human metapneumovirus type B (gene L) and types A and B (gene N), as well as the amplified fragment of the target gene, the amplicon size, the thermal profiles and the cycle number for the relevant viruses are reported in Table 1. PCR reaction was performed as reported (Rovida et al., 2005). Nucleic acids were extracted
| Virus                          | Target gene                        | Amplicon size (bp) | Thermal profile | Cycle | Primer pair                                                                 |
|-------------------------------|------------------------------------|--------------------|-----------------|-------|-----------------------------------------------------------------------------|
| Influenza A H3N2              | HA (291–897)                       | 606                | 94°C/1°C, 52°C/1°C | 52    | 5′-ctttttgttgaacgcagcaa-3 primer, 5′-gcttccatttggagtgatgcat-3 reverse        |
| Human parainfluenza virus-1   | HN (7692–7936)                    | 244                | 94°C/1°C, 55°C/1°C | 40    | 5′-ggaacaaggggtatatcagtt-3 primer, 5′-ggagttgttaagccaaagta-3 reverse        |
| Human parainfluenza virus 2   | HN (7498–7733)                    | 235                | 94°C/1°C, 55°C/1°C | 40    | 5′-ggaatcaatcgcaaaagctgt-3 primer, 5′-cctagatgatagatcccgctt-3 reverse       |
| Human metapneumovirus, subtype B | L (4121–4290)                  | 169                | 94°C/30°C, 72°C/30°C | 40    | 5′-tatgcctactataaaaggtcaa-3 primer, 5′-caccccagtctttcctaaag-3 reverse      |
| Human metapneumovirus, subtypes A and B | N (80–596)       | 516                | 94°C/1°C, 60°C/1°C, 72°C/1°C | 40    | 5′-gagatgtaggcacmacaacw-3 primer, 5′-gggtatcttttgagygcatc-3 reverse        |

Annealing temperature decreasing by 1°C/cycle.

2.3. Direct fluorescent antibody staining

Direct fluorescent antibody staining was applied to slides containing a sufficient number of cytocentrifuged respiratory epithelial columnar cells, which were stained with a pool (SimulFluor Respiratory Screen reagent, Chemicon International Inc., Temecula, CA) of fluorescein-labeled MAbS to conventional respiratory viruses (influenza A and B, human parainfluenza virus 1–4, human respiratory syncytial virus, and human adenovirus). The single fluorescein-conjugated MAbS (included in the pool) to individual conventional respiratory viruses were obtained from the same source (Chemicon). In addition, MAb to human coronavirus OC43 (Chemicon) was preliminarily found to perform satisfactorily in identifying the reference strain as well as NPA-positive samples, whereas MAb to human coronavirus 229E was not and, thus, was abandoned. No MAb to human metapneumovirus was found to be commercially available.

2.4. Rapid and conventional respiratory virus recovery in cell cultures

Each NPA sample processed for cell cultures was inoculated onto each of two shell vials of a mixture (MIX) of A549 and MvILu (ratio of 1:1) cells (Huang and Turchek, 2000) for rapid virus detection, as well as onto each of two tubes of LLC-MK2 and MDCK cell lines for recovery of conventional respiratory viruses in cell cultures. Shell vials were centrifuged at 1800 rpm for 45 min and incubated at 33°C in a 5% CO2 atmosphere. After 48 h, one shell vial was fixed and stained with MAbS, as for direct fluorescent antibody staining. In case of negative results, the second shell vial was stained 7 days p.i. As for conventional virus isolation, LLC-MK2 and MDCK cells inoculated with NPA samples were incubated at 33°C and observed daily for CPE up to 7 days. Then, cells were trypsinized (one tube) and stained with MAbS, as for direct fluorescent antibody staining. In case of negative results, cultures (second tube) were kept under observation for two additional weeks.

2.5. Human metapneumovirus recovery and quantification in cell cultures

In preliminary experiments, the following cell cultures were used for human metapneumovirus recovery: secondary AGMK, human embryonic lung fibroblasts (HEp-2), LLC-MK2, Vero, and HEp-2. Subsequently, LLC-MK2 were selected as optimal for virus isolation and propagation. An in-house prepared guinea pig hyperimmune serum was used for human metapneumovirus identification (both types A and B) in cell cultures. After adaptation to growth in cell cultures, human metapneumovirus was quantified by CPE as 50% tissue culture infectious doses (TCID50).

Using Nuclisens® Iso Kit (BioMerieux, Lyon, France). PCR products were examined on 3% agarose gel.
on serial tenfold dilutions of infected LLC-MK2 supernatants harvested at 4, 7, 10, and 14 days p.i. In addition, human metapneumovirus RNA in both cell culture supernatants and NPAs was semiquantified, following RT, by diluting viral cDNA from the original samples.

2.6. Human metapneumovirus phylogenetic analysis

The great majority of human metapneumovirus strains of this study were classified into types A and B according to a recent report by Van den Hoogen et al. (2004a), and differently from another recent paper by Boivin et al. (2004), where classification of types is apparently inverted. Viral sequences of the amplified gene N fragment (nt 80–nt 596) of human metapneumovirus isolates as well as reference strains were aligned with the Clustal W program version 1.2, whereas sequence similarity comparisons were carried out with the Megalign program (DNASTAR Inc., Madison, WI). Distances between pairs of nucleotide sequences were calculated by using the DNAdist (with Kimura’s two-parameter method) modules in the Philip package, version 3.572 (Felsenstein, Department of Genetics, University of Washington, Seattle, WA). The percent genetic identity within the N gene were calculated between the four major branches of the tree. The Philip (upgplot) program was used to construct phylogenetic trees with nucleotide sequences by means of the neighbour-joining method from the same distance matrices. Bootstrap support was determined by 100 resamplings of the sequences.

3. Results

3.1. Improved RT-PCR protocol for human metapneumovirus detection

During this study, it was observed that only human metapneumovirus strains of type A were detected by using the primer pair originally published for gene L amplification by Van den Hoogen et al. (2003). Thus, while the original primer pair was kept for detection of type A strains, a new primer set matching the same nt position was designed on the basis of gene L sequences published in GenBank for type B strains. As a result, several type B strains could be detected retrospectively in our patient series already examined, while starting from 1 March 2004, patients were prospectively investigated by using both pairs of primers in a mixture. In addition, a fragment of the human metapneumovirus gene N (nt 80–nt 596) was amplified to confirm results obtained by amplifying the gene L and to construct the phylogenogram by using degenerate primers, as reported in Table 1.

### Table 2

Human metapneumovirus (type A)-positive nasopharyngeal aspirate samples inoculated and propagated at 37°C onto African green monkey kidney (AGMK), Vero, HEp-2, LLC-MK2 and human embryonic lung (HELF) cell cultures

| Spec. # | cell culture passage | Detection in cell cultures by RT-PCR | CPE |
|---------|----------------------|--------------------------------------|-----|
| ... | ... | Positive 2+ | ... |
| 6621, AGMK/1 | 6621, AGMK/2 | Positive 2+ | ... |
| ... | ... | Positive 3+ | ... |
| 6621, AGMK/9 | 6621, AGMK/2-HELF/1 | Positive 4+ (syncytia and single refractile cells) | ... |
| ... | ... | Positive 0 | ... |
| 6621, AGMK/2-HELF/2 | 6621, AGMK/2-HELF/3 | Negative 0 | ... |
| ... | ... | Positive 0 | ... |
| 6621, AGMK/2-LLC-MK2/1 | 6621, AGMK/2-LLC-MK2/2 | Positive 0 | ... |
| ... | ... | Positive 0 | ... |
| 6621, AGMK/2-LLC-MK2/5 | 6621, AGMK/2-LLC-MK2/8 | Positive 1+ | ... |
| ... | ... | Positive 0 | ... |
| 6621, Vero/1 | 6621, Vero/2 | Positive 0 | ... |
| ... | ... | Negative 0 | ... |
| 3636, AGMK/1 | 3636, AGMK/2 | Positive 1+ | ... |
| ... | ... | Positive 3+ | ... |
| 3636, AGMK/5 | 3636, AGMK/3-HELF/1 | Positive 0 | ... |
| ... | ... | Negative 0 | ... |
| 3636, AGMK/3-HELF/2 | 3636, AGMK/5-LLC-MK2/1 | Positive 1+ | ... |
| ... | ... | Positive 2+ | ... |
| 3636, AGMK/5-LLC-MK2/2 | 3636, AGMK/5-LLC-MK2/5 | Positive 3+ | ... |
| ... | ... | Positive 0 | ... |
| 3636, Vero/1 | 3636, Vero/2 | Negative 0 | ... |
| ... | ... | Positive 0 | ... |

Virus growth as detected by RT-PCR and cytopathic effect (CPE).
Initially, following inoculation of two NPA samples strongly positive for human metapneumovirus by RT-PCR, virus isolation was attempted, following overnight adsorption, in sAGMK, LLC-MK2, Vero, and HEp-2 fed with E-MEM containing trypsin (2 μg/ml) in the absence of fetal calf serum. Inoculated cell cultures were incubated at 37°C (Table 2). A positive RT-PCR signal was detected in the supernatant of all three cell cultures types at 7–14 days after inoculation. Following the first passage of the whole cell cultures (cells and supernatant) onto homologous cells, viral RNA signal increased in sAGMK and markedly decreased in Vero and HEp-2 cells. Upon second passage, the RNA signal further increased in sAGMK, while it disappeared in Vero and HEp-2 cells. At this time, propagation of the two human metapneumovirus isolates onto HELF and LLC-MK2 was attempted. As shown in Table 2, while the attempt failed in HELF after two passages, it was successful in LLC-MK2 for both human metapneumovirus strains.

The virus was semiquantified for viral RNA by RT-PCR and quantified in infectivity titer by CPE. Following 2 h adsorption and extensive washings, viral RNA started appearing in the medium 24 p.i. (Fig. 1A), reaching ∼5 log10 RNA copies/ml at day 4, and a stable peak RNA titer of >7 log10 RNA copies/ml between days 7 and 14 (Fig. 1B). Based on CPE (infectivity), the titer reached 3 log10 TCID50/ml at day 4, 4 log10 at day 10, and 7 log10 at day 14 (Fig. 1B). Thus, at day 14 the same mean viral titer was measured by either CPE or RNA. However, viral RNA peak titer (within limit of semiquantitation by endpoint dilution) was reached more than a week in advance with respect to infectivity peak titer.

3.2. Phylogenetic analysis of human metapneumovirus strains circulating in northern Italy in the winter–spring season 2003–2004

Sequencing of the first fragment of gene N (nt 80–nt 596) and the subsequent phylogenetic analysis of human metapneumovirus strains recovered during the winter season 2003–2004 showed that both types A and B of human metapneumovirus as well as their relevant subtypes A1–A2 and B1–B2 were circulating in northern Italy (Fig. 2). However, based on analysis of 36/40 human metapneumovirus strains, the circulation rate was very different for different subtypes, as follows: 72% for A2 (n = 26 strains), 14% for B2 (n = 5), 11% for B1 (n = 4), and 3% for A1 (n = 1) strains. The phylogenetic tree was drawn using the following reference strains: NL/1/00 (Van den Hoogen et al., 2004a) for A1, NL/17/00 (Van den Hoogen et al., 2004a) and CAN97-83 (Bastien et al., 2003) for A2, NL/1/99 (Van den Hoogen et al., 2004a) and CAN97-82 (Bastien et al., 2003), for B1, and NL/1/94 (Van den Hoogen et al., 2004a) and CAN 98-75 (Bastien et al., 2003) for B2 strains. Sequence analysis showed that nucleotide identity of type A versus type B strains was 83.51–87.81%. The amino acid (aa) identity of type A versus type B strains was 94.09–94.77%.

3.3. Distribution of human metapneumovirus and other respiratory virus infections

Among 306 pediatric patients examined during the winter–spring season 2003–2004, 140 (45.8%) were positive for one or more respiratory viruses by either immunological or molecular methods (Fig. 3). Patients affected by a single infection were 53 (17.3%) for human respiratory syncytial virus, 30 (9.8%) for human metapneumovirus, 23 (7.5%) for influenza viruses (22 influenza A and 1 influenza B), 8 (2.6%) for human coronavirus, 7 (2.3%) for human adenovirus, and 4 (1.3%) for human parainfluenza virus. In addition, 10 (3.3%) patients were affected by coinfections [3 human metapneumoviruses + human coronavirus (2 human metapneumoviruses type A + human coronavirus 229E, and 1 human metapneumovirus type B + human coronavirus OC43), 1 human metapneumovirus type A + influenza A, 2 human metapneumoviruses type A + human adenovirus, 1 human respiratory syncytial virus + human metapneumovirus, 1 human respiratory syncytial virus + human coronavirus 229E + human metapneumovirus type A, and 1 human respiratory syncytial virus + human coronavirus 229E + human metapneumovirus type B].
1 human respiratory syncytial virus type B + influenza A, 1 human respiratory syncytial virus + human adenovirus, 1 influenza B + human coronavirus OC43, and 1 influenza A + human adenovirus), and 5 (1.6%) patients were affected by sequential respiratory virus infections (1 human metapneumovirus type A followed by human respiratory syncytial virus, 1 human metapneumovirus type A followed by adenovirus, 1 influenza A followed by human metapneumovirus type A, 1 human metapneumovirus type B followed by human respiratory syncytial virus + human coronavirus, and, finally,
Fig. 3. Incidence of different respiratory virus infections in 306 pediatric patients admitted to hospital in the winter–spring season 2003–2004. Numbers at the top of each histogram indicate the absolute number of patients. 1 influenza A followed by human respiratory syncytial virus). Thus, the overall number of paediatric patients affected by the human metapneumovirus infection was 40 (13.1%) including 6 coinfections and 3 sequential infections, the number of patients with human respiratory syncytial virus infection was 58 (18.9%) including 2 coinfections and 3 sequential infections, the number of patients with influenza was 29 (27 influenza A and 2 influenza B, 9.5%) including 4 coinfections and 1 sequential infection, and, finally, the number of patients with human adenovirus infection was 12 (3.9%) including 3 coinfections and 2 sequential infections.

The monthly distribution showed the peak of human respiratory syncytial virus infections in March, while the peak of human metapneumovirus and influenzavirus infections was reached in February (Fig. 4). While human respiratory syncytial virus was predominant compared to human metapneumovirus in January, March and April, in February the rate of the two virus infections was identical (14 cases observed for either virus).

Both the incidence of human respiratory syncytial virus (42/53, 79.2%) and human metapneumovirus (23/31, 74.2%) infections during the first year of life and the relative proportion of human respiratory syncytial virus and human metapneumovirus infections during each of the first 12 months of life were found not to be significantly different ($P > 0.05$).

As for the circulation rate, type A human metapneumovirus infected 22/29 (75.9%) and type B 7/29 (24.1%) patients, while type A human respiratory syncytial virus infected 24/43 (55.8%) and type B human respiratory syncytial virus infected 19/43 (44.2%) patients. As for the distribution of eight human coronavirus strains examined, seven were 229E-like (group I) and one OC43-like (group II).

3.4. Pathogenicity of human metapneumovirus in hospitalized children

As shown in Fig. 5, of the 40 human metapneumovirus-infected children examined at the Pediatric Emergency Department, 15 (37%) were dismissed (outpatients) after medical examination, while 25 (63%) were admitted to the Respiratory Disease ward (inpatients). For comparison, of the 59 human respiratory syncytial virus-infected children, only eight (14%) were outpatients, and as many as 51 (86%) were inpatients, thus documenting a significantly higher number of inpatients in the human respiratory syncytial virus-infected as compared to the human metapneumovirus-infected group ($P=0.006, \chi^2$ test). On the contrary, the number of inpatients with lower respiratory tract infections was not significantly different in the two groups of patients, as was the number of infants with double infections, which were mostly restricted to inpatients in both groups (Fig. 5).
Table 3

| Patient #, age (months) | Sequential NPAs | Human metapneumovirus RNA semiquantitation in NPA samples (log_{10} RNA copies/ml) | Clinical follow-up |
|------------------------|-----------------|---------------------------------------------------------------------------------|-------------------|
| 43, 3                  | 3 January 2004  | 6.4                                                                             | Bronchiolitis      |
|                        | 5 January 2004  | 7.4                                                                             | Worsening          |
|                        | 12 January 2004 | <3.0                                                                            | Improvement        |
| 3453, 7                | 20 February 2004| 7.4                                                                             | Bronchiolitis      |
|                        | 26 February 2004| 4.4                                                                             | Improvement        |
| 3500, 2                | 20 February 2004| 9.4                                                                             | Rhinitis           |
|                        | March 1 2004    | 7.4                                                                             | Partial recovery   |
| 3611, 6                | 23 February 2004| 8.6                                                                             | Bronchiolitis      |
|                        | 26 February 2004| 7.4                                                                             | Unchanged          |
| 3921, 12               | 2 February 2004 | 7.4                                                                             | Pneumonia          |
|                        | 5 March 2004    | 3.4                                                                             | Improvement        |
|                        | 10 March 2004   | <3.0                                                                            | Resolution         |

### 3.5. Duration of human metapneumovirus excretion and correlation of viral load in NPA and clinical symptoms

Whenever possible, patients positive for human metapneumovirus and other respiratory viruses in NPA samples collected in the following days and weeks in order to: (i) determine the duration of viral excretion; (ii) correlate viral load with clinical symptoms. It was preliminarily observed that human metapneumovirus was often excreted with respiratory secretions for more than 10 days. In more detail, the duration of human metapneumovirus excretion in the eight children undergoing multiple sampling during follow-up showed a trend towards persistence of virus shedding for more than 2–3 weeks in patients with pneumonia or bronchiolitis, whereas patients with upper respiratory tract involvement shed virus mostly for less than 7 days. In addition, as shown for patients reported in Table 3, the highest viral RNA tier was detected concomitantly with the peak of clinical symptoms interesting either the upper or the lower respiratory tract, while the decrease in viral load was mostly associated with the resolution of local clinical symptoms. More extensively, this data seems to suggest that the drop in viral titer dissociated from the resolution of clinical symptoms may help to exclude the etiologic role of human metapneumovirus in the current respiratory infection.

Six infants and young children were tested for presence of viral RNA in serum 3–9 (mean 6) days after first virus detection in NPA. No virus was detected in serum of any of these patients, whether human metapneumovirus was still present in NPA or not. Unfortunately, no serum was available for testing at time of first viral RNA detection in NPA.

### 4. Discussion

In the present report, the circulation rate of human metapneumovirus among respiratory viruses causing respiratory tract infections of hospitalized children in the winter–spring season 2003–2004 was studied to gain insight on diagnostic, epidemiological and clinical aspects of human metapneumovirus infections in pediatric patients of northern Italy.

Diagnosis was mostly done by RT-PCR. However, we and others (Maertzdorf et al., 2004) observed that some strains could not be detected by the RT-PCR method using the L6–L7 primer pair originally used by Van den Hoogen et al. (2001) for human metapneumovirus detection because of a number of mismatches with respect to the target sequences of the four genetic lineages and, particularly, of the two sub-lineages B (B1 and B2). In fact, when we designed a new primer pair on the basis of the published sequences of the gene L of human metapneumovirus B strains, a new series of human metapneumovirus-positive NPA samples was identified among previously negative respiratory specimens, as determined by using L6–L7 primer pair. Subsequently, a mixture of the two primer pairs was routinely employed for human metapneumovirus detection in clinical samples. As a result, types and subtypes A and B of human metapneumovirus strains could be detected. In this respect, it seems important to recall that real-time RT-PCR specific for gene N has been shown to be more sensitive than RT-PCRs specific for genes L, F, M, and P of human metapneumovirus strains (Côté et al., 2003).

In parallel, optimal cell cultures systems for human metapneumovirus isolation were investigated in view of potentially detecting human metapneumovirus types or strains not detected by RT-PCR. Why has human metapneumovirus been detected about 50 years after initiation of Medical Virology, i.e. after introduction of cell culture technology? Obvious answer to this question is the recent extended use of molecular techniques. However, tertiary AGMK cell cultures have been essential for the initial human metapneumovirus detection in respiratory samples (Van den Hoogen et al., 2001) and, subsequently, several groups have reported human metapneumovirus isolation in conventional cell cultures such as AGMK or HEp-2 or in well-known cell lines such as LLC-
MK2 (Boivin et al., 2002; Chun et al., 2003; Hamelin et al., 2004; Van den Hoogen et al., 2004b). Very recently, a subclone of Vero cells has been mentioned as particularly susceptible to human metapneumovirus isolation (Van den Hoogen et al., 2004b). Our study confirms that the most sensitive cell cultures systems for human metapneumovirus CPE detection are AGMK and LLC-MK2. In this respect, LLC-MK2 cells may be preferable since widely available and giving a clear-cut, although delayed, CPE. It is well known that, among avian MPV (aMPV) four different types (A, B, C, and D) have been thus far identified. This suggests that a parallel cultural and molecular approach to diagnosis of human metapneumovirus infections may be desirable in view of the potential identification of new human metapneumovirus types.

Phylogenetic analysis of human metapneumovirus strains in different countries was based on the comparison of sequences of genes L, N, F, or P (Van den Hoogen et al., 2001, 2004a; Boivin et al., 2002, 2004; Bastien et al., 2003; Mackay et al., 2004) and consistently allowed to cluster all strains into two major groups, referred to as A and B, and each major group into two subgroups (A1 and A2, or B1 and B2). This classification was initially introduced by the Dutch authors who discovered human metapneumovirus (Van den Hoogen et al., 2001), and should be accepted by the other groups, keeping in mind that the starting point of any classification attempt should be the entire genome sequence of the prototype strain NL/1/00, which was reported as A1 subtype (Van den Hoogen et al., 2004a). A recent publication considering the prototype Dutch strain as belonging to A2 subgroup may generate some confusion (Boivin et al., 2004).

Limitations of our study are restriction to a single respiratory virus season, lack of detection of rhinoviruses, and the severity of clinical symptoms requiring admission to the hospital. Within these limits, as reported by others, human metapneumovirus reached its peak circulation in February–March together with human respiratory syncytial virus and influenzaviruses, and was the most highly circulating virus in the pediatric patient population after respiratory syncytial virus. In addition, human metapneumovirus was largely predominant, along with human respiratory syncytial virus, during the first year of life. These epidemiological findings are substantially in agreement with most of the recently published papers (Boivin et al., 2002; Van den Hoogen et al., 2003, 2004a, 2004b; Esper et al., 2004; McAdam et al., 2004; Mullins et al., 2004; Williams et al., 2004).

Human metapneumovirus was second to human respiratory syncytial virus only, both in the circulation rate and the severity of clinical symptoms. This was documented by the fact that, unlike patients infected by other viruses and in agreement with previous reports (Bastien et al., 2003; Maggi et al., 2003), the number of human respiratory syncytial virus-infected was significantly greater than that of human metapneumovirus-infected inpatients, while the relative proportion of inpatients with lower respiratory tract infections as well as the number of children with double infections was comparable in the two groups. However, both coinfections and sequential infections appeared to be a more severe prognostic factor, since they were nearly exclusively detected in inpatients. As for duration of human metapneumovirus excretion, it appeared to be even longer than that previously reported (Van den Hoogen et al., 2004b). This may represent a route of virus dissemination after resolution of acute clinical symptoms and in the presence of low viral load in NPA's. Our data on the correlation of viral load in NPA and clinical symptoms support this conclusion.

In fact, the preliminary observation of a trend towards a correlation between levels of viral RNA load in NPA samples and presence of clinical symptoms indicates that the amount of virus present in respiratory secretions is a direct marker of the etiologic involvement of human metapneumovirus in the current respiratory disease. Levels of viral RNA detected in the respiratory tract during the acute phase of a respiratory disease are somewhat comparable to those found in the upper respiratory tract of experimentally infected hamsters (Skiaidopoulos et al., 2004). However, it is important to recall that experimental animal models, including nonhuman primates, do not mimic human metapneumovirus disease, even though high levels of neutralizing antibodies which are cross-protective against heterologous strains can be induced (MacPhail et al., 2004; Skiaidopoulos et al., 2004).

In all cases of human metapneumovirus infection examined in blood, no viral RNA could be detected, in contrast to data recently published by Maggi et al. (2003). This finding could be explained by the fact that we examined blood some days after onset of respiratory infection and, thus, virus could have already been cleared from blood. The presence of respiratory viruses or viruses infecting mucosal tissues in blood may be surprising. However, it may help recalling that recently influenza virus A RNA and human adenovirus DNA have been detected in blood of patients with acute encephalopathy in association with influenza virus A infection (Steininger et al., 2003). In addition, human rotavirus antigenemia has been detected in blood of infants with acute gastroenteritis (Blutt et al., 2003).

In conclusion, our study demonstrates that: (i) human metapneumovirus is a major viral pathogen in the Italian pediatric patient population, second only to human respiratory syncytial virus; (ii) the severity of human metapneumovirus infections approaches that of human respiratory syncytial virus, while virus excretion may persist even after 2–3 weeks; (iii) there is a preliminary indication of a correlation of human metapneumovirus load in respiratory secretions and the stage of viral infection.

Acknowledgments

We thank Linda D’Arrigo for revision of the English. We are indebted to the technical staff of the Servizio di Virologia for test performance. In addition, the contribution of Daniela Sartori for typing the manuscript is greatly acknowledged.
References

Allan A, Giroues R, Ito P, Wadler G. Polypeptide chain reaction for detection of adenoviruses in stool samples. J Clin Microbiol 2002;40:2649–57.

Bastien N, Ward D, Van Casteren F, Branica K, Lee SHS, McNabb G, et al. Human metapneumovirus infection in the Canadian population. J Clin Microbiol 2003;41:1462–6.

Bhatt SE, Kirkwood CD, Parreno V, Warfield KL, Ciarlet M, Estes MK, et al. Rotavirus antigenemia and viremia: a common event? Lancet 2003;362:1445–9.

Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Côté S, et al. Virological features and clinical manifestations associated with human metapneumoviruses: a new paramyxovirus responsible for acute respiratory tract infections in all age groups. J Infect Dis 2002;186:1336–4.

Boivin G, Mackay I, Sloots TP, Maathé S, Freymuth F, Wolf D, et al. Global genetic diversity of human metapneumovirus fusion gene. Emerg Infect Dis 2004;10:1154–7.

Chan PKS, Tam JS, Chan E, Wu A, Li C-K, et al. Human metapneumovirus detection in patients with severe acute respiratory syndrome. Emerg Infect Dis 2003;9:1056–63.

Cones MT, Perez-Breia P, Garcia ML, Casas I. Simultaneous detection of influenza A, B, and C viruses, respiratory syncytial virus, and adenovirus in clinical samples by multiplex reverse transcription nested-PCR assays. J Virol 2003;79:1432–44.

Côté S, Abed Y, Boivin G. Comparative evaluation of real-time PCR assays for detection of the human metapneumovirus. J Clin Microbiol. 2003.41:3631–5.

Echevarría JE, Edman DD, Swierzewska EM, Holloway BP, Anderson LJ. Simultaneous detection and identification of human parainfluenza viruses 1, 2, and 3 from clinical samples by multiplex PCR. J Clin Microbiol 1998;36:1384–91.

Esper F, Martínez RJ, Rouche D, Wölfel C, Ferguson D, Landry ML, et al. A 1-year experience with human metapneumovirus in children aged <5 years. J Infect Dis 2004;189:1388–96.

Falsy AR, Edman D, Anderson LJ, Waldt EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis 2003;187:785–90.

Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:549–6.

Greenall MJ, McNamara PS, Dowie W, Flanagan B, Smyth RL, Hart CA. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. Emerg Infect Dis 2003;9:732–5.

Hamelin ME, Abed Y, Boivin G. Human metapneumovirus: a new player among respiratory viruses. Clin Infect Dis 2004;38:976–80.

Huang Y-T, Turchek BM. Mink lung cells and mixed mink lung and A549 cells for rapid detection of influenza viruses and other respiratory viruses. J Clin Microbiol 2000;38:422–3.

Landy ML, Ferguson D, Cohen S, Peric TCT, Edman DD. Detection of human metapneumovirus in clinical samples by immunofluorescence staining of shell vial centrifugation cultures prepared from three different cell lines. J Clin Microbiol 2000;38:1593–2.

Mackey JM, Bialek-Szweczko S, Walianzaman Z, Chilow FG, Froego DC, Luanagan S, et al. Use of the P gene to genotype human metapneumoviruses. J Virol 2004;78:10479–84.

MacNeil J, Stoeckelau R, Briesel M, Roggenski M. High prevalence of human metapneumovirus infection in young children and genetic heterogeneity of the viral isolates. J Clin Microbiol 2003;41:3043–5.

McAdam AJ, Hasenbeck ME, Feldman RA, Cole SE, Oeflmann JJ, Riley AM, et al. Human metapneumovirus infection as children tested at a tertiary care hospital. J Infect Dis 2004;190:26–7.

Mullins JA, Edman DD, Weinberg GA, Edwards K, Hall CB, Walker FJ, et al. Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg Infect Dis 2004;10:705–5.

Nisson MD, Siebert JJ, Mackay JM, Sloots TP, Wolthers SJ. Evidence of human metapneumovirus in Australian children. Med J Austral 2002;176:74–8.

Pelletier G, Diny P, Abed Y, Boivin G. Respiratory tract reinfections in the new human metapneumovirus in an immunocompromised child. Emerg Infect Dis 2002;8:976–8.

Pereville E, Sarasin A, Visai L, Revelli MG, Grena G. 2005. Rapid detection of human metapneumovirus strains in nasopharyngeal aspirates and shell vial cultures by monoclonal antibodies. J Clin Microbiol., in press.

Postmaen SM, Low DE, Henry B, Finkelestein S, Rose D, Green K, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348:1995–2005.

Rovida F, Pereville E, Zavattori M, Torrellas M, Sarasin A, Campomani G, et al. Monoclonal antibodies versus reverse-transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital. J Med Virol 2005;75:336–46.

Skiadopoulos MH, Buicchiessi S, Buchholz UJ, Riggs JM, Surman SR, Amaro-Cabristo E, et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the (F) protein is a major contributor to this antigenic relatedness. J Virol 2004;78:6827–37.

Steininger C, Popow-Knopp T, Lefel H, Seiser A, Goß I, Djambaljian S, et al. Acute encephalopathy associated with influenza A virus infection. Clin Infect Dis 2003;36:567–74.

Stockton J, Ellis JS, Savelle M, Clewley JP, Zambon MC. Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses. J Clin Microbiol 1998;36:2990–5.

Van den Hoogen BG, Brexltnbr TM, Osterhaus ADME, Fouchier RAM. Analysis of the genomic sequence of a human metapneumovirus. Virology 2002;295:110–32.

Van den Hoogen BG, De Jong JC, Green J, Kaakeen T, De Groot R, Fouchier RAM, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001;7:719–24.

Van den Hoogen BG, Herfst S, Spong L, Cana PA, Forkoo-No1 E, de Swart RL, et al. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 2004;10:656–8.

Van den Hoogen BG, Osterhaus ADME, Fouchier RAM. Clinical impact and diagnosis of human metapneumovirus infection. Pediatr Infect Dis J 2004;23:23–25.

Van den Hoogen BG, van Doornum GJ, Beckens JC, Cornelissen JJ, Bryen WE, De Groot R, et al. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalised patients. J Infect Dis 2003;184:171–7.

Vaira S, Batum E, Schirhauser R, Flessel M, Roggenkoff M. High prevalence of human metapneumovirus infection in young children and genetic heterogeneity of the viral isolates. J Clin Microbiol 2003;41:3043–5.

Williams JF, Harris PA, Tolfson SJ, Huffkut-Bush RL, Phippsstrea JM, Edwards KM, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004;350:443–50.